GlassScriptPhysician profile
Albert S Arceri
NPI 1114413697
$22,390.49
in general payments reported to CMS, 2019-2025
13 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2023: $1,676 · 2024: $1,811 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $5,399 · Travel and Lodging: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,500.00 |
| Food and Beverage | $5,399.40 |
| Travel and Lodging | $357.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,363.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,053.93 | 2023-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $519.50 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $347.76 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $236.27 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $189.55 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $189.51 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $136.25 | 2023-2025 | Trintellix |
| Lundbeck LLC | $101.34 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $90.60 | 2023-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $81.83 | 2025 | Fanapt |
| Corium, LLC | $65.60 | 2023-2024 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.74 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Arceri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.